# Matthew Vincent

> Matthew Vincent is AdvanCell's Boston-based chief business officer, a biochemist and patent attorney whose career has moved between the laboratory, the law firm and the biotech negotiating table. He helped lead business development around Ocata Therapeutics before its acquisition by Astellas, served as senior vice president of business development at POINT Biopharma before its acquisition by Eli Lilly, and now works on AdvanCell's partnerships and U.S. expansion around a vertically integrated lead-212 radiopharmaceutical platform.

- **Role:** Chief Business Officer at AdvanCell
- **Organizations:** AdvanCell, POINT Biopharma, Avacta Group, Arisaph Pharmaceuticals, Ocata Therapeutics, Advanced Cell Technology, INVENTtheFUTURE.BIO, TractBIO, Multiclonal Therapeutics, Ropes & Gray, Foley Hoag, Lahive & Cockfield, Alliance for Regenerative Medicine
- **Education:** B.S. in Chemistry, summa cum laude, Worcester Polytechnic Institute, Ph.D. in Biochemical Sciences, Tufts University School of Medicine, J.D., cum laude, Suffolk University Law School
- **Known for:** Built a career spanning laboratory science, patent law, company formation and biotechnology business development., Led business development, contract negotiations and due diligence at Ocata Therapeutics through its acquisition by Astellas., Led licensing activities at POINT Biopharma before Eli Lilly completed its acquisition of the radiopharmaceutical company in December 2023.

## Career timeline

- **1991-1997** — Worked as an associate at the intellectual-property firm Lahive & Cockfield while completing his J.D.
- **1997-2001** — Partner at Foley Hoag, working in life-sciences intellectual property and related strategy.
- **2001-2009** — Partner at Ropes & Gray, advising biotechnology and chemical-sector clients on patents, licensing and drug-development strategy.
- **2009-2023** — Principal of INVENTtheFUTURE.BIO, alongside operating and advisory work in life sciences.
- **2011-2015** — Director of business development at Advanced Cell Technology, later renamed Ocata Therapeutics; led commercial affairs and supported diligence and negotiations through Ocata's acquisition by Astellas.
- **2015-2017** — Led corporate development and therapeutic innovation strategy at Arisaph Pharmaceuticals.
- **2017-2021** — Joined Avacta as vice president of therapeutics business development and later served as senior vice president of business development and innovation strategy.
- **2022-2023** — Senior vice president of business development at POINT Biopharma, leading licensing work and strategic partnerships before Eli Lilly completed its acquisition of POINT.
- **2024-present** — Chief business officer at AdvanCell, based in Greater Boston.
- **2026** — Represented AdvanCell's Greater Boston expansion publicly as the company secured a 128,000-square-foot Andover headquarters and manufacturing facility and closed a $315 million Series D.

## Achievements

- Built a career spanning laboratory science, patent law, company formation and biotechnology business development.
- Led business development, contract negotiations and due diligence at Ocata Therapeutics through its acquisition by Astellas.
- Led licensing activities at POINT Biopharma before Eli Lilly completed its acquisition of the radiopharmaceutical company in December 2023.
- Co-inventor on life-sciences patents including compositions and methods for lung regeneration and tumor-microenvironment-activated drug-binder conjugates.
- Co-author of scientific work on gastrointestinal and epithelial stem cells.
- Served on the Alliance for Regenerative Medicine executive committee from 2011 through 2014.
- Contributed to transactions and strategic partnerships involving Eli Lilly, Pfizer, GSK, Bristol Myers Squibb, Merck, Genentech/Roche, Moderna and Astellas.

## Latest updates

- **2026-07** — AdvanCell closed an oversubscribed and upsized $315 million Series D to advance ADVC001, expand its lead-212 platform and build U.S. manufacturing infrastructure.
- **2026-06** — AdvanCell announced a 128,000-square-foot U.S. global headquarters and future manufacturing center in Andover, Massachusetts.
- **2026-04** — Vincent presented AdvanCell's planned Andover expansion to the town's Select Board, describing the region's biotech talent base and a prospective training relationship with UMass Lowell.
- **2026-01** — Shared AdvanCell's collaboration and exclusive licensing agreement with 48Hour Discovery for a peptide-based lead-212 radiotherapeutic program.

## Links

- Website: https://www.advancell.com.au
- LinkedIn: https://www.linkedin.com/in/matthewvincent

---

Profile page: https://yespress.io/matthew-vincent
Published by YesPress — https://yespress.io
Last updated: 2026-09-27